Huntingdon Life Sciences De-Listed From Pink Sheets

For Immediate Release:

May 1, 2006
Huntingdon Life Sciences De-Listed From Pink Sheets
Mysterious Full-Page Ad in New York Times Credits ALF
New York, NY: The campaign to stop the killing at Huntingdon Life Sciences (HLS) notched another important victory against the notorious animal testing lab. Last week, HLS which traded on the Pink Sheets as Life Sciences Research Inc. (Stock Symbol: LSRI) was dropped off of the lowest recognized board onto the unregulated Grey Market, as they lost their sole market maker, Vertical Group. In a terse statement to activists, Vertical Group commented they did “not support animal cruelty or abuse and never [have].”

In a related bizarre event, an unknown group or individual placed a full- page advertisement in the New York Times on Friday, picturing a masked man and the caption “I Control Wall Street.” A group calling itself NYSE Hostage claimed responsibility for the ad, but it is unclear who the group is, and calls to the contact number listed on a referenced website went unreturned. Activists view the ad as another failed attempt to draw attention away from Huntingdon Life Science’s failing business by playing on peoples fears and trying to paint effective advocates for animals as terrorists.

Huntingdon Life Sciences has been exposed in five separate undercover investigations abusing animals and killing 500 per day testing such products as oven cleaners and pesticides. Before losing their NYSE listing in September, the company had lost their listing on the London Stock Exchange over four years ago, after a sustained campaign by activists who exposed atrocities occurring inside HLS facilities.

Camille Hankins, Press Officer with the Animal Liberation Press Office and New York coordinator with Win Animal Rights (WAR), a local organization protesting HLS/LSRI, said “Huntingdon Life Sciences is on financial quicksand. In just 8 months, LSRI has dropped from a near listing on the prestigious NYSE to being dumped unceremoniously off the Pink Sheets. I think that the NYSE did investors a service, by putting a halt to the listing. LSRI is deeply in debt and losing more customers and money every day.”